Key FDA committee unanimously recommends its first vaccine since 2023
An FDA advisory committee unanimously recommended Moderna's new mRNA flu vaccine for adults 50 and older, marking the first vaccine approval by the committee since 2023. The vaccine uses mRNA technology similar to that used in the COVID-19 vaccine and may offer faster production and stronger protection against flu strains. The recommendation comes despite previous challenges, including initial rejection of the application and concerns over funding cuts for mRNA research.
An FDA committee unanimously recommended Moderna's new mRNA flu vaccine for adults 50 and over, the first vaccine approval since 2023.
The vaccine uses mRNA technology, which allows for faster development and potentially stronger protection against flu strains, improving public health preparedness.
This news highlights progress in vaccine science and resilience in the face of political and public skepticism, offering hope for better health outcomes.
Upbeat Bytes summarizes in its own words and links to the original publisher — it doesn't host the article.